Dr. Patrick Amadeus Ryscavage, MD

Dr. Ryscavage practices at University of Maryland Medical Center Midtown Campus in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Ryscavage's NPI, 1902062755, was assigned on July 31, 2008. Dr. Ryscavage graduated from Georgetown University School Of Medicine in 2004. Dr. Ryscavage's Maryland license number on file is D72445.

Dr. Ryscavage's primary practice is University of Maryland Medical Center Midtown Campus, at 827 Linden Avenue, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 225-8996.

Dr. Ryscavage's primary practice is University of Maryland Medical Center Midtown Campus in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Ryscavage is also affiliated with University of Maryland Medical Center. The medical group on file is University of Maryland Medical Center Gastroenterology and Hepatology. Dmand AI also links Dr. Ryscavage to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ryscavage practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Ryscavage's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Ryscavage is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Ryscavage's licenses on file in 4 states: Maryland, Illinois, District of Columbia and Virginia.

Dmand AI lists acute skin infection, hiv/aids, joint or bone infection and pneumonia among the conditions Dr. Ryscavage treats.

CMS data shows 339 Medicare services from Dr. Ryscavage across 5 procedure codes in 2024, for 150 Medicare patients. Medicare paid $30,237 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 150 Medicare patients who saw Dr. Ryscavage in 2024. The largest group is under 65, with 70 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 63% are also on Medicaid. Their average risk score is 3.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ryscavage's median patient age at 58, with 37% women.

In 2024, Dr. Ryscavage wrote 1,254 Medicare Part D claims for 82 patients. 52% of them were for generic drugs. CMS names the drug for 975 of them, across 37 drugs with 11 or more claims each, at $1,392,506 in total drug cost. In 2023, CMS named 939 claims across 34 drugs.

Dr. Ryscavage accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ryscavage as offering telehealth.

Dmand AI links 28 papers to Dr. Ryscavage, published from 2011 to 2025. 2011 was the busiest year, with 3. The most frequent topics are HIV Infections, Anti-HIV Agents and Antiretroviral Therapy, Highly Active. Dr. Ryscavage has published most often in J Acquir Immune Defic Syndr. Dr. Ryscavage's most frequent co-authors are Babafemi Olapoju Taiwo, MD, Joseph J. Eron, MD and William Christopher Mathews, MD.

CMS Open Payments shows 14 general payments to Dr. Ryscavage from 1 drug or device company from 2017 to 2020. Speaker and faculty fees make up the largest share, 45% of the total. Theratechnologies Inc. paid the most, $5,534.

Dr. Ryscavage graduated from Georgetown University School Of Medicine in 2004.

Dr. Ryscavage is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.